LAUSR

1. Black M, Barsoum IB, Truesdell P, et al. Activation of the PD-1/PDL-1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget. 2016;7:10557–10567. 2. Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017:24–26. 3. Ali HR, Glont SE, Blows FM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488–1493. 4. Zhang Y, Morgan R, Chen C, et al. Mammary-tumoreducated B cells acquire LAP/TFG-beta and PD-L1 expression and suppress anti-tumor responses. Int Immunol. 2016;28:423–433. 5. Patnaik A, Kang SP, Rasco D, et al. Phase 1 study of pembrolizumab (MK-3475; andit-pd-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286–4293. 6. Nanda R, Chow L, Claire Dees E, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase 1b KEYNOTE-012 study. J Clin Oncol. 2016;34: 2460–2467. 7. Rugo HS, Delord J, Im S, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptorpositive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res. 2018;24: 2804–2811. 8. Adams S, Schmid P, Rugo H, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol. 2017;35(15 suppl): 1008. 9. Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY2. J Clin Onc. 2017;35(15 suppl); Abstract 506.